HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
TCMD
Tactile Systems Technology, Inc.
TCMD's fundamentals are strong: revenue grew 14% and earnings per share grew 32%, though free cash flow fell 27%. At 26x earnings, it's trading in line with its usual 27x. Analysts expect that strong growth to continue, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
TCMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
TCMD's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
TCMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $13.15 | -51% |
| Forward | 21x | $26.82 | — |
| Current | 26x | $26.82 | — |
| Fair | 27x | $27.39 | +2.1% |
| Expensive | 89x | $91.05 | +240% |
Historical ranges are pointers, not guarantees.
TCMD's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
TCMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
TCMD has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
TCMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.25 | +23% |
| Q3 2026 | $1.02 | +32% |
| Q2 2026 | $1.07 | +73% |
| Q1 2026 | $0.87 | +32% |
| Q4 2025 | $0.82 | +17% |
| Q3 2025 | $0.77 | +13% |
| Q2 2025 | $0.62 | -56% |
| Q1 2025 | $0.66 | -46% |
| Q4 2024 | $0.70 | -43% |
TCMD has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over TCMD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
TCMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $91.9M | +7.1% |
| Q2 2026 | $85.7M | +8.6% |
| Q1 2026 | $75.3M | +23% |
| Q4 2025 | $103.6M | +21% |
| Q3 2025 | $85.8M | +17% |
| Q2 2025 | $78.9M | +7.8% |
| Q1 2025 | $61.3M | +0.3% |
| Q4 2024 | $85.6M | +10% |
TCMD's revenue has grown year over year for 22 quarters in a row: $92M last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -2.3 points |
| Q2 2026 | 8% | +2.8 points |
| Q1 2026 | -2% | +5.4 points |
| Q4 2025 | 18% | +3.5 points |
| Q3 2025 | 13% | +3.5 points |
| Q2 2025 | 5.2% | -2.8 points |
| Q1 2025 | -7.4% | -2.6 points |
| Q4 2024 | 15% | -0.6 points |
TCMD has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over TCMD on cash flow, with more consistent year-over-year improvement.
TCMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.4M | +24% |
| Q2 2026 | $2M | -86% |
| Q1 2026 | -$1.2M | -3153% |
| Q4 2025 | $16.8M | +5.8% |
| Q3 2025 | $9.2M | -0.9% |
| Q2 2025 | $14.4M | +14% |
| Q1 2025 | $38K | -91% |
| Q4 2024 | $15.9M | -9% |
TCMD generated $29M in free cash flow over the past year, down 27% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over TCMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
TCMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -13K shares |
| 1 year | +2.4% | +533K shares |
| 3 years | -3.4% | -803K shares |
| 5 years | +16% | +3.3M shares |
| Available history | +17% | +3.4M shares |
TCMD has 23M diluted shares, up 2.4% from a year ago, despite $13M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6.2M |
| Q2 2026 | $5.3M |
| Q1 2026 | $1.1M |
| Q4 2025 | $1,000 |
| Q3 2025 | — |
| Q2 2025 | $16.5M |
| Q1 2025 | $10M |
TCMD spent $13M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
TCMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -2.3x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.4x | Net Cash |
TCMD has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
TCMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.2 | Neutral |
| Stochastic | 45.3 | Neutral |
TCMD's weekly RSI is 57 (neutral) and its Stochastic is 45 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
TCMD PE vs Healthcare Sector
| Metric | TCMD | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 1.7% above |
| PE % | 49 | 29 | 20 pts above |
TCMD is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
TCMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.7 | 13% above |
| 20 week MA | $25.1 | 6.9% above |
| 50 week MA | $26.2 | 2.3% above |
| 100 week MA | $20.3 | 32% above |
| 200 week MA | $18.0 | 49% above |
TCMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
TCMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.3 | $41.6 | -39% |
| 2021 | $41.6 | $20.2 | -51% |
| 2022 | $20.2 | $11.7 | -42% |
| 2023 | $11.7 | $14.3 | +22% |
| 2024 | $14.3 | $17.3 | +21% |
| 2025 | $17.3 | $29.7 | +72% |
| 2026 YTD | $29.7 | $26.8 | -9.6% |
TCMD has the edge over HIMS on returns for 2026, with the stronger performance.